FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2810290010> ?p ?o ?g. }

• W2810290010 endingPage "1393" @default.
• W2810290010 startingPage "1383" @default.
• W2810290010 abstract "In X-linked hypophosphatemia (XLH), inherited loss-of-function mutations in the PHEX gene cause excess circulating levels of fibroblast growth factor 23 (FGF23), leading to lifelong renal phosphate wasting and hypophosphatemia. Adults with XLH present with chronic musculoskeletal pain and stiffness, short stature, lower limb deformities, fractures, and pseudofractures due to osteomalacia, accelerated osteoarthritis, dental abscesses, and enthesopathy. Burosumab, a fully human monoclonal antibody, binds and inhibits FGF23 to correct hypophosphatemia. This report summarizes results from a double-blind, placebo-controlled, phase 3 trial of burosumab in symptomatic adults with XLH. Participants with hypophosphatemia and pain were assigned 1:1 to burosumab 1 mg/kg (n = 68) or placebo (n = 66) subcutaneously every 4 weeks (Q4W) and were comparable at baseline. Across midpoints of dosing intervals, 94.1% of burosumab-treated participants attained mean serum phosphate concentration above the lower limit of normal compared with 7.6% of those receiving placebo (p < 0.001). Burosumab significantly reduced the Western Ontario and the McMaster Universities Osteoarthritis Index (WOMAC) stiffness subscale compared with placebo (least squares [LS] mean ± standard error [SE] difference, –8.1 ± 3.24; p = 0.012). Reductions in WOMAC physical function subscale (–4.9 ± 2.48; p = 0.048) and Brief Pain Inventory worst pain (–0.5 ± 0.28; p = 0.092) did not achieve statistical significance after Hochberg multiplicity adjustment. At week 24, 43.1% (burosumab) and 7.7% (placebo) of baseline active fractures were fully healed; the odds of healed fracture in the burosumab group was 16.8-fold greater than that in the placebo group (p < 0.001). Biochemical markers of bone formation and resorption increased significantly from baseline with burosumab treatment compared with placebo. The safety profile of burosumab was similar to placebo. There were no treatment-related serious adverse events or meaningful changes from baseline in serum or urine calcium, intact parathyroid hormone, or nephrocalcinosis. These data support the conclusion that burosumab is a novel therapeutic addressing an important medical need in adults with XLH.© 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals, Inc." @default.
• W2810290010 created "2018-07-10" @default.
• W2810290010 creator A5003985986 @default.
• W2810290010 creator A5006764055 @default.
• W2810290010 creator A5008403948 @default.
• W2810290010 creator A5009280176 @default.
• W2810290010 creator A5009292672 @default.
• W2810290010 creator A5012177668 @default.
• W2810290010 creator A5021526213 @default.
• W2810290010 creator A5021541475 @default.
• W2810290010 creator A5026404969 @default.
• W2810290010 creator A5033263730 @default.
• W2810290010 creator A5035626178 @default.
• W2810290010 creator A5036019764 @default.
• W2810290010 creator A5059341158 @default.
• W2810290010 creator A5062703256 @default.
• W2810290010 creator A5067626549 @default.
• W2810290010 creator A5080565019 @default.
• W2810290010 creator A5082366563 @default.
• W2810290010 creator A5085949704 @default.
• W2810290010 creator A5086053349 @default.
• W2810290010 creator A5088012799 @default.
• W2810290010 creator A5088108970 @default.
• W2810290010 date "2018-06-26" @default.
• W2810290010 modified "2023-10-15" @default.
• W2810290010 title "A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis" @default.
• W2810290010 cites W1964204750 @default.
• W2810290010 cites W1985742682 @default.
• W2810290010 cites W1997282564 @default.
• W2810290010 cites W2004177560 @default.
• W2810290010 cites W2008101181 @default.
• W2810290010 cites W2021852822 @default.
• W2810290010 cites W2035451751 @default.
• W2810290010 cites W2036143549 @default.
• W2810290010 cites W2063100453 @default.
• W2810290010 cites W2069528022 @default.
• W2810290010 cites W2078117827 @default.
• W2810290010 cites W2090490099 @default.
• W2810290010 cites W2094262605 @default.
• W2810290010 cites W2125079553 @default.
• W2810290010 cites W2140330355 @default.
• W2810290010 cites W2287107235 @default.
• W2810290010 cites W2316811098 @default.
• W2810290010 cites W2469427057 @default.
• W2810290010 cites W4230052913 @default.
• W2810290010 cites W4245666729 @default.
• W2810290010 cites W4292689881 @default.
• W2810290010 doi "https://doi.org/10.1002/jbmr.3475" @default.
• W2810290010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29947083" @default.
• W2810290010 hasPublicationYear "2018" @default.
• W2810290010 type Work @default.
• W2810290010 sameAs 2810290010 @default.
• W2810290010 citedByCount "205" @default.
• W2810290010 countsByYear W28102900102017 @default.
• W2810290010 countsByYear W28102900102018 @default.
• W2810290010 countsByYear W28102900102019 @default.
• W2810290010 countsByYear W28102900102020 @default.
• W2810290010 countsByYear W28102900102021 @default.
• W2810290010 countsByYear W28102900102022 @default.
• W2810290010 countsByYear W28102900102023 @default.
• W2810290010 crossrefType "journal-article" @default.
• W2810290010 hasAuthorship W2810290010A5003985986 @default.
• W2810290010 hasAuthorship W2810290010A5006764055 @default.
• W2810290010 hasAuthorship W2810290010A5008403948 @default.
• W2810290010 hasAuthorship W2810290010A5009280176 @default.
• W2810290010 hasAuthorship W2810290010A5009292672 @default.
• W2810290010 hasAuthorship W2810290010A5012177668 @default.
• W2810290010 hasAuthorship W2810290010A5021526213 @default.
• W2810290010 hasAuthorship W2810290010A5021541475 @default.
• W2810290010 hasAuthorship W2810290010A5026404969 @default.
• W2810290010 hasAuthorship W2810290010A5033263730 @default.
• W2810290010 hasAuthorship W2810290010A5035626178 @default.
• W2810290010 hasAuthorship W2810290010A5036019764 @default.
• W2810290010 hasAuthorship W2810290010A5059341158 @default.
• W2810290010 hasAuthorship W2810290010A5062703256 @default.
• W2810290010 hasAuthorship W2810290010A5067626549 @default.
• W2810290010 hasAuthorship W2810290010A5080565019 @default.
• W2810290010 hasAuthorship W2810290010A5082366563 @default.
• W2810290010 hasAuthorship W2810290010A5085949704 @default.
• W2810290010 hasAuthorship W2810290010A5086053349 @default.
• W2810290010 hasAuthorship W2810290010A5088012799 @default.
• W2810290010 hasAuthorship W2810290010A5088108970 @default.
• W2810290010 hasBestOaLocation W28102900101 @default.
• W2810290010 hasConcept C114276007 @default.
• W2810290010 hasConcept C124490489 @default.
• W2810290010 hasConcept C126322002 @default.
• W2810290010 hasConcept C141071460 @default.
• W2810290010 hasConcept C142724271 @default.
• W2810290010 hasConcept C204787440 @default.
• W2810290010 hasConcept C27081682 @default.
• W2810290010 hasConcept C2776164576 @default.
• W2810290010 hasConcept C2777871287 @default.
• W2810290010 hasConcept C2778049618 @default.
• W2810290010 hasConcept C2778573388 @default.
• W2810290010 hasConcept C2779286237 @default.
• W2810290010 hasConcept C2781208988 @default.
• W2810290010 hasConcept C519063684 @default.
• W2810290010 hasConcept C71924100 @default.

• next